PK Study of Dapagliflozin in Pediatric Subjects With T2DM

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

July 1, 2012

Primary Completion Date

September 1, 2014

Study Completion Date

September 1, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin

Tablet, Oral, 2.5 mg, Single-dose

DRUG

Dapagliflozin

Tablet, Oral, 5 mg, Single-dose

DRUG

Dapagliflozin

Tablet, Oral, 10 mg, Single-dose

Trial Locations (17)

14222

Women And Children'S Hopsital Of Buffalo, Buffalo

15224

Children'S Hospital Of Pittsburgh Of Upmc, Pittsburgh

19104

Children'S Hospital Of Philadelphia, Philadelphia

30322

Emory University, Atlanta

32827

Nemours Childrens Hospital, Orlando

35233

The Children Hospital Of Alabama, Birmingham

38103

Methodist Le Bonheur Hlthcare, Memphis

40202

Kosair Charities Pediatric Clinical Research Unit, Louisville

43606

Promedica Toledo Children'S Hospital, Toledo

43608

Mercy Children'S Hospital, Toledo

44150

Local Institution, Guadalajara

64108

Childrens Mercy Hospital, Kansas City

64460

Local Institution, Monterrey

71103

Lsuhsc-Shreveport, Shreveport

78207

Christus Santa Rosa Childrens Hospital, San Antonio

90036

Axis Clinical Trials, Los Angeles

91910

Local Institution, Veracruz

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY